FORNARO, MARCO
 Distribuzione geografica
Continente #
NA - Nord America 2.082
AS - Asia 1.420
EU - Europa 1.251
SA - Sud America 349
AF - Africa 91
OC - Oceania 4
Totale 5.197
Nazione #
US - Stati Uniti d'America 2.013
SG - Singapore 670
BR - Brasile 267
IT - Italia 251
DE - Germania 218
CN - Cina 202
RU - Federazione Russa 196
FI - Finlandia 156
HK - Hong Kong 142
SE - Svezia 137
FR - Francia 108
VN - Vietnam 107
GB - Regno Unito 67
IN - India 57
CA - Canada 43
AR - Argentina 37
BD - Bangladesh 35
JP - Giappone 33
ZA - Sudafrica 31
CI - Costa d'Avorio 27
IQ - Iraq 25
ID - Indonesia 22
TR - Turchia 22
PL - Polonia 21
MX - Messico 19
NL - Olanda 17
PK - Pakistan 17
BE - Belgio 14
EC - Ecuador 14
SA - Arabia Saudita 14
AT - Austria 13
PH - Filippine 13
LT - Lituania 9
VE - Venezuela 9
UA - Ucraina 8
UZ - Uzbekistan 8
CO - Colombia 7
CZ - Repubblica Ceca 7
ES - Italia 7
IR - Iran 7
CL - Cile 6
KE - Kenya 6
MA - Marocco 6
MY - Malesia 6
TN - Tunisia 6
AM - Armenia 5
KZ - Kazakistan 5
PY - Paraguay 5
AU - Australia 4
JM - Giamaica 4
CH - Svizzera 3
ET - Etiopia 3
IL - Israele 3
KG - Kirghizistan 3
LB - Libano 3
SI - Slovenia 3
TH - Thailandia 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AZ - Azerbaigian 2
BG - Bulgaria 2
BH - Bahrain 2
CG - Congo 2
EE - Estonia 2
EG - Egitto 2
IE - Irlanda 2
KR - Corea 2
NG - Nigeria 2
NP - Nepal 2
OM - Oman 2
ZW - Zimbabwe 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BO - Bolivia 1
CM - Camerun 1
CR - Costa Rica 1
DK - Danimarca 1
GF - Guiana Francese 1
HR - Croazia 1
JO - Giordania 1
KW - Kuwait 1
MK - Macedonia 1
MR - Mauritania 1
MT - Malta 1
MU - Mauritius 1
PE - Perù 1
PS - Palestinian Territory 1
PT - Portogallo 1
QA - Qatar 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TL - Timor Orientale 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
UY - Uruguay 1
Totale 5.197
Città #
Singapore 386
Ashburn 341
San Jose 176
Chandler 170
Hong Kong 142
Munich 138
Helsinki 120
Fairfield 114
Nyköping 114
Beijing 95
Los Angeles 61
Dallas 60
Houston 57
New York 55
Lauterbourg 53
Cambridge 50
Woodbridge 43
Moscow 41
Seattle 40
Bari 36
Wilmington 36
Falkenstein 33
Ho Chi Minh City 32
São Paulo 32
Abidjan 27
Ann Arbor 27
Council Bluffs 27
Hanoi 26
Lawrence 26
Santa Clara 24
Turku 22
Buffalo 20
Tokyo 19
Roxbury 18
Warsaw 18
Frankfurt am Main 17
Inglewood 17
Johannesburg 17
Chicago 15
London 15
Brussels 14
Toronto 14
Des Moines 13
Montreal 13
Milan 12
Poplar 12
Brooklyn 11
Denver 11
Jakarta 11
El Paso 10
Stockholm 10
Florence 9
Manchester 9
Mexico City 9
Orem 9
Paris 9
Phoenix 9
Princeton 9
San Francisco 9
Amsterdam 8
Bacolod City 8
Baghdad 8
Jyväskylä 8
Mumbai 8
Pescara 8
Boston 7
Chennai 7
Dhaka 7
Naples 7
Rome 7
Ankara 6
Atlanta 6
Bengaluru 6
Boardman 6
Nuremberg 6
Redwood City 6
Rio de Janeiro 6
Riyadh 6
Salt Lake City 6
Tashkent 6
Belo Horizonte 5
Da Nang 5
Düsseldorf 5
Haiphong 5
Illkirch-Graffenstaden 5
Modugno 5
Nairobi 5
Ottawa 5
Porto Alegre 5
Pune 5
Quito 5
Shanghai 5
Tunis 5
Vienna 5
Yerevan 5
Brno 4
Campinas 4
Cape Town 4
Columbus 4
Dong Ket 4
Totale 3.201
Nome #
Survival and prognostic factors from a multicentre large cohort of unselected Italian systemic sclerosis patients 222
AB0836 Drug retention rate of the first tnf inhibitor in radiographic and non radiographic axial spondyloarthritis: data from a multicenter study 187
A Bayesian mixed treatment comparison of efficacy of biologics and small molecules in early rheumatoid arthritis 179
AB0041 Serum Amyloid A Stimulates The Induction of Inflammatory Mediators in Monocytes from Behçet's Disease Patients: A Proof of Concept Study 164
Clinical, histologic and prognostic features of clinically amyopathic dermatomyositis 161
Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases 156
Lipids and atherogenic indices fluctuation in rheumatoid arthritis patients on long-term tocilizumab treatment 152
Anti-SAE dermatomyositis: clinical and histologic characteristics from a monocentric Italian cohort 144
THU0153 The effect of 5-years b-dmards treatment on different 10-years cardiovascular risk scores applied in rheumatoid arthritispatients 142
AB0245 PREDICTORS OF BIOLOGIC THERAPY DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS AFTER REMISSION ACHIEVEMENT: A MONOCENTRIC OBSERVATIONAL STUDY FROM BIOLOGIC APULIAN REGISTRY (BIOPURE) 126
Perivascular and endomysial macrophages expressing VEGF and CXCL12 promote angiogenesis in anti-HMGCR immune-mediated necrotizing myopathy 125
The Impact of Biologic Drugs on High-Density Lipoprotein Cholesterol Efflux Capacity in Rheumatoid Arthritis Patients 119
Severe muscle damage with myofiber necrosis and macrophage infiltrates characterize anti-Mi2 positive dermatomyositis 117
The autoinflammatory side of recurrent pericarditis: Enlightening the pathogenesis for a more rational treatment 112
Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings 110
Body mass index and adipokines/cytokines dysregulation in systemic sclerosis 110
Sindrome anti-sintetasi: due casi di anti-EJ (anti-glycyl-tRNAsintetasi) 104
Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors 100
Cartilage damage: clinical approach 100
High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry 97
Effectiveness and safety of secukinumab in patients with moderate-severe psoriasis: A multicenter real-life study 95
Plasma pentraxin 3 in idiopathic inflammatory myopathies: a possible new biomarker of disease activity 90
Comparison of Adalimumab to Other Targeted Therapies in Rheumatoid Arthritis: Results from Systematic Literature Review and Meta-Analysis 90
Long-term efficacy of adding intravenous immunoglobulins as treatment of refractory dysphagia related to myositis: a retrospective analysis 90
Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis 90
Elevated Expression of ADAM10 in Skeletal Muscle of Patients with Idiopathic Inflammatory Myopathies Could Be Responsible for FNDC5/Irisin Unbalance 90
Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus 88
Complete Hydatidiform Mole Mimicking Sacroiliitis 88
Influence of changes in cholesterol levels and disease activity on the 10 years cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients 87
Cardiovascular risk estimation with 5 different algorithms before and after 5 years of bDMARD treatment in rheumatoid arthritis 86
Validity of Machine Learning in Predicting Giant Cell Arteritis Flare After Glucocorticoids Tapering 83
Effectiveness of Tapering Rituximab Dose in Idiopathic Inflammatory Myopathies: Real-World Data from a Monocentric Study 83
Preliminary data on post market safety profiles of covid 19 vaccines in rheumatic diseases: Assessments on various vaccines in use, different rheumatic disease subtypes, and immunosuppressive therapies: A two-centers study 81
Long-term safety of rituximab in rheumatic patients with previously resolved hepatitis B virus infection 79
Phosphorylated signal transducer and activator of transcription 3 (pSTAT3) is highly expressed in CD14+ circulating cells of scleroderma patients 79
A Machine Learning Approach for Predicting Sustained Remission in Rheumatoid Arthritis Patients on Biologic Agents 74
Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes 71
Anti-SARS-CoV-2 antibody decay after vaccination and immunogenicity of the booster dose of the BNT162b2 mRNA vaccine in patients with psoriatic arthritis on TNF inhibitors 70
Effectiveness of biological targeted therapies may discriminate seronegative from seropositive rheumatoid arthritis 66
Prevalence and management of tuberculosis infection in Apulian rheumatologic patients treated with biologics: An observational cohort 10-year study from the BIOPURE registry 65
Histopathologic Features of Fibrotic Knee Synovitis in a Young Adult with Seronegative Rheumatoid Arthritis 64
Letters to the editors 63
Erratum: Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus (Rheumatology (2020) 59 (1188) DOI: 10.1093/rheumatology/kez442) 61
Mepolizumab versus benralizumab for eosinophilic granulomatosis with polyangiitis (EGPA): A European real-life retrospective comparative study 60
Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group 55
Safety Profile and Low Risk of Disease Relapse After BNT162b2 mRNA SARS-CoV-2 Vaccination in Patients With Rare Rheumatic Diseases 54
Effectiveness and safety of filgotinib in rheumatoid arthritis patients: data from the GISEA registry 53
The impact of multimorbidity on QoL in inflammatory myopathies: COVAD cluster analysis 53
Subcutaneous immunoglobulin therapy for refractory skin thickening in rapidly progressive systemic sclerosis: A case report and literature review 52
Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course 52
Safety and effectiveness in switching from reference to biosimilar rituximab in rheumatoid arthritis patients: real world experience from a single Italian rheumatology centre 51
Paradoxical Pustular Psoriasis in a Patient with Psoriatic Arthritis on Secukinumab Treatment 47
Effectiveness of ixekizumab over 24 months in different clinical scenarios in psoriatic arthritis: results from the Gruppo Italiano Studio Early Arthritis multicentric prospective registry 44
Real-life effectiveness of rituximab in different subsets of idiopathic inflammatory myopathies 38
Predictors of long-term clinical remission in rheumatoid arthritis 36
Rituximab-induced hypogammaglobulinaemia in patients affected by idiopathic inflammatory myopathies: a multicentre study 32
Mobile session fixation attack in micropayment systems 28
Relapses of idiopathic inflammatory myopathies after vaccination against COVID-19: a real-life multicenter Italian study 26
Power Doppler signal at the enthesis and bone erosions are the most discriminative OMERACT ultrasound lesions for SpA: results from the DEUS (Defining Enthesitis on Ultrasound in Spondyloarthritis) multicentre study 25
Integrating large language models in medicine: a study of Claude 2’s performance in MDAAT scoring for idiopathic inflammatory myopathies 22
Occult HBV infection may negatively impact on drug survival in patients with rheumatoid arthritis on treatment with a first biologic drug. An appraisal from the biologic apulian registry (BIOPURE) 21
Retention rate of biologic and targeted synthetic anti-rheumatic drugs in elderly rheumatoid arthritis patients: data from GISEA registry 20
Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA Registry 19
Response to: ‘Response to: “Influence of changes in cholesterol levels and disease activity on the 10-year cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients” by Fornaro et al‘ by Agca et al 16
Aquaporin-4 downregulation in dysphagic patients with idiopathic inflammatory myopathies: myofiber vulnerability and inflammation drivers 15
Neuropathic pain in spondyloarthritis: Decoding its prevalence, risk factors, and impact on disease activity 15
Turning the Tide against Herpes Zoster in Rheumatoid Arthritis Patients Treated with JAK Inhibitors 14
Clinical Characteristics of Anti-Synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome Project 8
Totale 5.416
Categoria #
all - tutte 23.888
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.888


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202160 0 0 0 0 0 0 0 0 0 19 31 10
2021/2022226 9 2 5 10 9 11 25 14 17 30 32 62
2022/2023455 46 76 30 31 30 69 9 66 61 6 19 12
2023/2024221 17 45 13 19 13 41 9 6 3 7 3 45
2024/20251.364 42 13 62 26 25 136 188 247 65 95 174 291
2025/20262.676 388 151 218 350 415 170 284 105 304 291 0 0
Totale 5.416